FDA accepts new drug application from Melinta's Baxdela

CABP is pneumonia that is infected outside theMedical(http://facilityThe most common pathogens are streptococcus pneumoniae, haemophilus influenzae type flue goecole and atypical bacteria (e.gchlamydia pneumoniae, mycoplasma pneumoniae, Legionella)today, Melinta Therapeutics(http:// announcedthatFDA(http://accepted the company's application for a supplementarynew drug(http://(sNDA) for Baxdela (http:// and granted it priority review eligibilitythis sNDA application extends Baxdela's indications to treat community-acquired bacterial pneumonia (CABP)The FDA is expected to respond by October 24about baxdelaBaxdela is an innovative broad-spectrum antibiotic that has been approved by the FDA to treat acute bacterial skin and skin structure infections (ABSSSI)This antibiotic is effective against both gram-negative and positive bacteria, and can treat methicillin-resistant Staphylococcus aureus (MRSA)Baxdela has been awarded the fda for theof Theof Infectious DiseasesProducts (http://(QIDP)In thetrial(http://, patients with CABP were treated with Baxdela or moxifloxacinThe results show that Baxcela meets the non-disadvantage standard in efficacy compared with MoxishaAt the same time, Baxdela exhibits good safety and tolerance